<p>尽管已经有了强劲的表现，<strong>信隆健康 (深圳)</strong> (SZSE:002105) 的股票仍在持续上涨，过去三十天上涨了 57%。回顾更长的时间，令人鼓舞的是，该股票在过去一年中上涨了 67%。</p>
<p>尽管其股价大幅上涨，但仍然没有多少人认为信隆健康 (深圳) 的市销率（&#34;P/S&#34;）为 3 倍值得一提，因为中国休闲行业的中位数市销率大约为 3.5 倍。不过，简单忽视市销率并不明智，因为投资者可能会忽略一个独特的机会或一个代价高昂的错误。</p>
<p>查看我们对信隆健康 (深圳) 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30793753-ps-multiple-vs-industry-1-dark/1743459257793?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30793753-ps-multiple-vs-industry-1-dark/1743459257793"/></p>
<p>SZSE:002105 市销率与行业比较 2025 年 3 月 31 日</p>
<h3>信隆健康 (深圳) 最近的表现如何？</h3>
<p>例如，信隆健康 (深圳) 最近收入的下降值得深思。许多人可能期待公司在未来一段时间内克服令人失望的收入表现，这使得市销率没有下降。如果不是这样，现有股东可能会对股价的可持续性感到有些紧张。</p>
<p>尽管没有信隆健康 (深圳) 的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看公司在收益、收入和现金流方面的表现。</p>
<h2>收入增长指标对市销率的启示是什么？</h2>
<p>你唯一会觉得舒适的市销率是当公司的增长与行业紧密相连时。</p>
<p>回顾过去一年，公司收入出现了令人沮丧的 4.7% 的下降。过去三年也不太好，因为公司总共缩减了 57% 的收入。因此，股东们对中期收入增长率感到失望。</p>
<p>将这一中期收入轨迹与更广泛行业一年的 22% 的扩张预测进行比较，结果显得不太乐观。</p>
<p>考虑到这一点，我们发现信隆健康 (深圳) 的市销率超过了同行，这让人担忧。似乎大多数投资者忽视了最近糟糕的增长率，并希望公司业务前景能有所好转。只有最勇敢的人才会认为这些价格是可持续的，因为近期收入趋势的持续可能最终会对股价造成压力。</p>
<h2>最后的总结</h2>
<p>信隆健康 (深圳) 似乎重新受到青睐，价格的稳步上涨使其市销率回归到行业其他公司的水平。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>信隆健康 (深圳) 目前的市销率与行业其他公司持平，这让我们感到惊讶，因为其近期收入在中期内一直在下降，而行业却预计将增长。当我们看到收入在行业增长预测的背景下出现下滑时，预计股价可能会下降，从而使适度的市销率降低是有道理的。除非近期中期条件显著改善，否则投资者将很难接受当前的股价为合理价值。</p>
<p>我们不想过于泼冷水，但我们确实发现了 <strong>信隆健康 (深圳) 的 4 个警示信号</strong>（其中 2 个有点令人担忧！），你需要注意。</p>
<p>如果这些 <strong>风险让你重新考虑对信隆健康 (深圳) 的看法</strong>，请查看我们互动式的高质量股票列表，以了解还有哪些其他选择。</p>

信隆健康

<p>信隆健康（HL Corp）（深圳证券交易所代码：002105）在过去一个月内价格上涨了 57%，过去一年上涨了 67%。然而，其市销率（P/S）为 3 倍，相较于行业中位数 3.5 倍令人担忧，尤其是在公司最近的收入下降 4.7% 以及三年来下降 57% 的情况下。投资者可能对反弹过于乐观，但当前的市销率暗示如果收入趋势没有改善，股价可能会下跌。由于发现了四个警示信号，建议保持谨慎</p>

<p>Despite an already strong run, <strong>HL Corp (Shenzhen)</strong> (SZSE:002105) shares have been powering on, with a gain of 57% in the last thirty days. Looking back a bit further, it's encouraging to see the stock is up 67% in the last year.</p>
<div class="lb-trans"><p>尽管已经有了强劲的表现，<strong>信隆健康 (深圳)</strong> (SZSE:002105) 的股票仍在持续上涨，过去三十天上涨了 57%。回顾更长的时间，令人鼓舞的是，该股票在过去一年中上涨了 67%。</p>
</div><p>Although its price has surged higher, there still wouldn't be many who think HL Corp (Shenzhen)'s price-to-sales (or &#34;P/S&#34;) ratio of 3x is worth a mention when the median P/S in China's Leisure industry is similar at about 3.5x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.</p>
<div class="lb-trans"><p>尽管其股价大幅上涨，但仍然没有多少人认为信隆健康 (深圳) 的市销率（&#34;P/S&#34;）为 3 倍值得一提，因为中国休闲行业的中位数市销率大约为 3.5 倍。不过，简单忽视市销率并不明智，因为投资者可能会忽略一个独特的机会或一个代价高昂的错误。</p>
</div><p>Check out our latest analysis for HL Corp (Shenzhen)</p>
<div class="lb-trans"><p>查看我们对信隆健康 (深圳) 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30793753-ps-multiple-vs-industry-1-dark/1743459257793" alt="" original-src="https://images.simplywall.st/asset/chart/30793753-ps-multiple-vs-industry-1-dark/1743459257793"/></p>
<p>SZSE:002105 Price to Sales Ratio vs Industry March 31st 2025</p>
<div class="lb-trans"><p>SZSE:002105 市销率与行业比较 2025 年 3 月 31 日</p>
</div><h3>How Has HL Corp (Shenzhen) Performed Recently?</h3>
<div class="lb-trans"><h3>信隆健康 (深圳) 最近的表现如何？</h3>
</div><p>For instance, HL Corp (Shenzhen)'s receding revenue in recent times would have to be some food for thought. It might be that many expect the company to put the disappointing revenue performance behind them over the coming period, which has kept the P/S from falling. If not, then existing shareholders may be a little nervous about the viability of the share price.</p>
<div class="lb-trans"><p>例如，信隆健康 (深圳) 最近收入的下降值得深思。许多人可能期待公司在未来一段时间内克服令人失望的收入表现，这使得市销率没有下降。如果不是这样，现有股东可能会对股价的可持续性感到有些紧张。</p>
</div><p>Although there are no analyst estimates available for HL Corp (Shenzhen), take a look at this <strong>free</strong> data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>尽管没有信隆健康 (深圳) 的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看公司在收益、收入和现金流方面的表现。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The P/S?</h2>
<div class="lb-trans"><h2>收入增长指标对市销率的启示是什么？</h2>
</div><p>The only time you'd be comfortable seeing a P/S like HL Corp (Shenzhen)'s is when the company's growth is tracking the industry closely.</p>
<div class="lb-trans"><p>你唯一会觉得舒适的市销率是当公司的增长与行业紧密相连时。</p>
</div><p>Retrospectively, the last year delivered a frustrating 4.7% decrease to the company's top line. The last three years don't look nice either as the company has shrunk revenue by 57% in aggregate. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入出现了令人沮丧的 4.7% 的下降。过去三年也不太好，因为公司总共缩减了 57% 的收入。因此，股东们对中期收入增长率感到失望。</p>
</div><p>Weighing that medium-term revenue trajectory against the broader industry's one-year forecast for expansion of 22% shows it's an unpleasant look.</p>
<div class="lb-trans"><p>将这一中期收入轨迹与更广泛行业一年的 22% 的扩张预测进行比较，结果显得不太乐观。</p>
</div><p>With this in mind, we find it worrying that HL Corp (Shenzhen)'s P/S exceeds that of its industry peers. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent revenue trends is likely to weigh on the share price eventually.</p>
<div class="lb-trans"><p>考虑到这一点，我们发现信隆健康 (深圳) 的市销率超过了同行，这让人担忧。似乎大多数投资者忽视了最近糟糕的增长率，并希望公司业务前景能有所好转。只有最勇敢的人才会认为这些价格是可持续的，因为近期收入趋势的持续可能最终会对股价造成压力。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最后的总结</h2>
</div><p>HL Corp (Shenzhen) appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>信隆健康 (深圳) 似乎重新受到青睐，价格的稳步上涨使其市销率回归到行业其他公司的水平。一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>The fact that HL Corp (Shenzhen) currently trades at a P/S on par with the rest of the industry is surprising to us since its recent revenues have been in decline over the medium-term, all while the industry is set to grow. When we see revenue heading backwards in the context of growing industry forecasts, it'd make sense to expect a possible share price decline on the horizon, sending the moderate P/S lower. Unless the recent medium-term conditions improve markedly, investors will have a hard time accepting the share price as fair value.</p>
<div class="lb-trans"><p>信隆健康 (深圳) 目前的市销率与行业其他公司持平，这让我们感到惊讶，因为其近期收入在中期内一直在下降，而行业却预计将增长。当我们看到收入在行业增长预测的背景下出现下滑时，预计股价可能会下降，从而使适度的市销率降低是有道理的。除非近期中期条件显著改善，否则投资者将很难接受当前的股价为合理价值。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>4 warning signs for HL Corp (Shenzhen)</strong> (2 are a bit concerning!) that you need to be mindful of.</p>
<div class="lb-trans"><p>我们不想过于泼冷水，但我们确实发现了 <strong>信隆健康 (深圳) 的 4 个警示信号</strong>（其中 2 个有点令人担忧！），你需要注意。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on HL Corp (Shenzhen)</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对信隆健康 (深圳) 的看法</strong>，请查看我们互动式的高质量股票列表，以了解还有哪些其他选择。</p>
</div>

信隆健康（深圳）（SZSE:002105）股价大涨 57% 引发担忧